{
    "root": "a32e11e0-ff6b-486a-a8af-0d029934b24d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Azithromycin Dihydrate",
    "value": "20250307",
    "ingredients": [
        {
            "name": "Azithromycin Dihydrate",
            "code": "5FD1131I7S"
        },
        {
            "name": "croscarmellose sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "polyethylene glycol 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "polyvinyl alcohol, unspecified",
            "code": "532B59J990"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "azithromycin macrolide antibacterial indicated treatment patients mild moderate infections caused susceptible strains designated microorganisms conditions listed . recommended dosages durations therapy adult pediatric patient vary . [ ( 2 ) ]",
    "contraindications": "adult patients ( 2.1 ) infection recommended dose/duration therapy community-acquired pneumonia ( mild severity ) pharyngitis/tonsillitis ( second-line therapy ) skin/skin structure ( uncomplicated ) 500 mg single dose day 1 , followed 250 mg daily days 2 5 acute bacterial exacerbations chronic bronchitis ( mild moderate ) 500 mg single dose day 1 , followed 250 mg daily days 2 5 500 mg daily 3 days acute bacterial sinusitis 500 mg daily 3 days genital ulcer disease ( chancroid ) non-gonococcal urethritis cervicitis one single 1 gram dose gonococcal urethritis cervicitis one single 2 gram dose pediatric patients ( 2.2 ) infection recommended dose/duration therapy acute otitis media ( 6 months age older ) 30 mg/kg single dose 10 mg/kg daily 3 days 10 mg/kg single dose day 1 followed 5 mg/kg/day days 2 5 acute bacterial sinusitis ( 6 months age older ) 10 mg/kg daily 3 days community-acquired pneumonia ( 6 months age older ) 10 mg/kg single dose day 1 followed 5 mg/kg daily days 2 5 pharyngitis/tonsillitis ( 2 years age older ) 12 mg/kg daily 5 days",
    "warningsAndPrecautions": "azithromycin tablets usp , 250 mg supplied red , oval , film coated tablets containing azithromycin dihydrate equivalent 250 mg azithromycin . azithromycin tablets usp , 250 mg debossed `` oe `` one side `` 250 `` side . packaged bottles blister cards 6 tablets follows : bottles 30 tablets child-resistant closure ndc 51224-022-30 bottles 100 tablets child-resistant closure ndc 51224-022-50 bottles 500 tablets ndc 51224-022-60 cartons 1 blister card child-resistant package ( 6 tablets per blister card ) ndc 51224-022-06 cartons 3 blister cards child-resistant package ( 6 tablets per blister card ) ndc 51224-022-18",
    "adverseReactions": "patients known hypersensitivity azithromycin , erythromycin , macrolide , ketolide . ( 4.1 ) patients history cholestatic jaundice/hepatic dysfunction associated prior azithromycin . ( 4.2 )",
    "indications_original": "Azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see Dosage and Administration (2)]",
    "contraindications_original": "Adult Patients ( 2.1 ) Infection Recommended Dose/Duration of Therapy Community-acquired pneumonia (mild severity) Pharyngitis/tonsillitis (second-line therapy) Skin/skin structure (uncomplicated) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 Acute bacterial exacerbations of chronic bronchitis (mild to moderate) 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5 or 500 mg once daily for 3 days Acute bacterial sinusitis 500 mg once daily for 3 days Genital ulcer disease (chancroid) Non-gonococcal urethritis and cervicitis One single 1 gram dose Gonococcal urethritis and cervicitis One single 2 gram dose Pediatric Patients ( 2.2 ) Infection Recommended Dose/Duration of Therapy Acute otitis media (6 months of age and older) 30 mg/kg as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg/day on Days 2 through 5 Acute bacterial sinusitis (6 months of age and older) 10 mg/kg once daily for 3 days Community-acquired pneumonia (6 months of age and older) 10 mg/kg as a single dose on Day 1 followed by 5 mg/kg once daily on Days 2 through 5 Pharyngitis/tonsillitis (2 years of age and older) 12 mg/kg once daily for 5 days",
    "warningsAndPrecautions_original": "Azithromycin Tablets USP, 250 mg are supplied as red, oval, film coated tablets containing azithromycin dihydrate equivalent to 250 mg of azithromycin.\n                  Azithromycin Tablets USP, 250 mg are debossed \"OE\" on one side and \"250\" on the other side. These are packaged in bottles and blister cards of 6 tablets as follows:\n                  \n                     \n                     \n                     \n                        \n                           Bottles of 30 tablets with child-resistant closure\n                           NDC 51224-022-30\n                        \n                        \n                           Bottles of 100 tablets with child-resistant closure\n                           NDC 51224-022-50\n                        \n                        \n                           Bottles of 500 tablets\n                           NDC 51224-022-60\n                        \n                        \n                           Cartons of 1 blister card with child-resistant package (6 tablets per blister card)\n                           NDC 51224-022-06\n                        \n                        \n                           Cartons of 3 blister cards with child-resistant package (6 tablets per blister card)\n                           NDC 51224-022-18",
    "adverseReactions_original": "Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide drug. ( 4.1) Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. ( 4.2 )"
}